Stock Analysis

European Growth Stocks With Strong Insider Ownership

BIT:PHN
Source: Shutterstock

Amidst a challenging economic landscape marked by fresh trade tariffs and fluctuating market sentiment, European markets have experienced some turbulence, with the pan-European STOXX Europe 600 Index recently ending about 1.4% lower. Despite these headwinds, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between management and shareholders.

Advertisement

Top 10 Growth Companies With High Insider Ownership In Europe

NameInsider OwnershipEarnings Growth
Pharma Mar (BME:PHM)11.8%40.8%
Vow (OB:VOW)13.1%111.2%
Elicera Therapeutics (OM:ELIC)27.8%97.2%
Bergen Carbon Solutions (OB:BCS)12%50.8%
CD Projekt (WSE:CDR)29.7%36.8%
Devyser Diagnostics (OM:DVYSR)35.7%95.4%
Elliptic Laboratories (OB:ELABS)22.6%88.2%
Ortoma (OM:ORT B)27.7%68.6%
Nordic Halibut (OB:NOHAL)29.8%56.3%
Circus (XTRA:CA1)26%51.4%

Click here to see the full list of 236 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Pharmanutra (BIT:PHN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pharmanutra S.p.A. is a pharmaceutical and nutraceutical company that researches, designs, develops, and markets nutritional supplements and medical devices across Italy, Europe, the Middle East, South America, the Far East, and internationally with a market cap of €483.04 million.

Operations: Pharmanutra generates revenue through segments including Akern (€5.92 million), Italy (€70.24 million), and Foreign markets (€39.34 million).

Insider Ownership: 10.7%

Revenue Growth Forecast: 10.9% p.a.

Pharmanutra is experiencing robust growth, with earnings increasing by 29.4% over the past year and forecasted to grow 14.6% annually, outpacing the Italian market's average. Revenue is also expected to rise at a rate of 10.9% per year, exceeding local market trends. Recent financial results show significant improvements in sales and net income for 2024. The company announced a €1 dividend per share and presented at the Euronext Milan STAR Conference, indicating active engagement with investors.

BIT:PHN Ownership Breakdown as at Apr 2025
BIT:PHN Ownership Breakdown as at Apr 2025

Truecaller (OM:TRUE B)

Simply Wall St Growth Rating: ★★★★★★

Overview: Truecaller AB (publ) develops and publishes mobile caller ID applications for individuals and businesses across India, the Middle East, Africa, and internationally, with a market cap of approximately SEK23.46 billion.

Operations: The company's revenue segment primarily consists of Communications Software, generating SEK1.88 billion.

Insider Ownership: 29.7%

Revenue Growth Forecast: 20.1% p.a.

Truecaller is experiencing significant growth, with earnings forecasted to increase by 24.7% annually, surpassing the Swedish market average. Revenue is expected to grow over 20% per year. Recent partnerships with Telecom Egypt and Telness enhance its business offerings and security features, expanding its market presence. The company's recent iOS update introduces advanced caller ID capabilities, potentially boosting subscription revenue. Truecaller trades at a substantial discount compared to its estimated fair value, indicating potential investment appeal.

OM:TRUE B Ownership Breakdown as at Apr 2025
OM:TRUE B Ownership Breakdown as at Apr 2025

Nagarro (XTRA:NA9)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Nagarro SE, along with its subsidiaries, offers digital product engineering and technology solutions across North America, Central Europe, the rest of Europe, and internationally, with a market cap of €988.65 million.

Operations: The company generates revenue of €947.15 million from its computer services segment.

Insider Ownership: 11.8%

Revenue Growth Forecast: 10.3% p.a.

Nagarro is forecasted to grow its revenue by 10.3% annually, outpacing the German market's 6%, with earnings projected to rise at 15.69% per year. Despite high debt levels, it trades at a significant discount to its estimated fair value and analysts agree on a potential price increase of nearly 50%. Recent developments include the upcoming resignation of Supervisory Board Chair Carl Georg Dürschmidt, with succession plans set for June 2025 elections.

XTRA:NA9 Earnings and Revenue Growth as at Apr 2025
XTRA:NA9 Earnings and Revenue Growth as at Apr 2025

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About BIT:PHN

Pharmanutra

A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally.

Outstanding track record with excellent balance sheet.

Advertisement